Picton Mahoney Asset Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History
Bought
Maintained
Sold
Other funds holding STLN
DM
RG
VCIM
PGM
TM
AGM
SCM
CH
Picton Mahoney Asset Management's STLN Position: Q4 2021 in Review
Picton Mahoney Asset Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2021, closing a stake of 150,000 shares — an estimated $1.49M sold.
Picton Mahoney Asset Management first reported a position in STLN in Q2 2020 and held it in 5 quarters. The position peaked at $2.16M in Q4 2020. 21 funds tracked by Wall St. Rank hold STLN as of Q4 2021.
- Picton Mahoney Asset Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
- Picton Mahoney Asset Management sold 150,000 Starling Oncology Institute, Inc. Common Stock shares in Q4 2021, an estimated $1.49M.
- Picton Mahoney Asset Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2020 and held it in 5 quarters.
- Picton Mahoney Asset Management's Starling Oncology Institute, Inc. Common Stock position peaked at $2.16M in Q4 2020.
- 21 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2021.
Based on Picton Mahoney Asset Management's 13F filing for Q4 2021, filed 10 Feb 2022.